Investigational drug · Phase 3
HC-1119
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for MCRPC.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "HC-1119"
First trial start
2019
Apr 12, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HC-1119", any sponsor or status.
Conditions studied
As listed on its trial records.
- MCRPC
Largest trials
Live from ClinicalTrials.gov: studies naming "HC-1119" as an intervention, largest first.
- HC-1119 Adjuvant Treatment for Hospitalized COVID-19 PatientsPivotal-lookingStatus unknown
Applied Biology, Inc.Industry
NCT04986176 · 602 participants (planned) · Start Apr 15, 2022 · Primary completion Dec 31, 2022
Drug: HC-1119; Placebo · For: COVID-19 Respiratory Infection
- A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).Pivotal-lookingRecruiting
Hinova Pharmaceuticals Inc.Industry
NCT03851640 · 417 participants (planned) · Start Apr 12, 2019 · Primary completion Sep 2025
Drug: HC-1119; placebo · For: MCRPC
Sites: Shanghai, China
- HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Pivotal-lookingTerminated
Hinova Pharmaceuticals USA, Inc.Industry
NCT03850795 · 104 participants · Start Mar 15, 2021 · Primary completion Jun 28, 2024
Drug: HC-1119; Enzalutamide · For: Prostate Cancer Metastatic; Castration-resistant Prostate Cancer
Sites: Denver, Colorado; Washington D.C., District of Columbia; Jeffersonville, Indiana · 58 sites in all
- A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its PharmacokineticsCompleted
Hinova Pharmaceuticals Inc.Industry
NCT03776968 · 47 participants · Start Oct 24, 2017 · Primary completion Jan 15, 2018
Drug: HC1119 · For: Metastatic Castration Resistant Prostate Cancer
Sites: Shanghai, China
- A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.Completed
Hinova Pharmaceuticals Inc.Industry
NCT03774056 · 43 participants · Start Feb 10, 2017 · Primary completion Sep 26, 2018
Drug: HC-1119 · For: Metastatic Castration Resistant Prostate Cancer
Sites: Chengdu, China
Hinova Pharmaceuticals Inc.Industry
NCT03778047 · 10 participants · Start Feb 7, 2018 · Primary completion Oct 24, 2018
Drug: Enzalutamide; HC1119 · For: Metastatic Castration Resistant Prostate Cancer
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
- Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.
Wu J, Li X, Gu C, et al. · Signal Transduct Target Ther 2026
- Population Pharmacokinetics Modeling and Simulation of Deutenzalutamide, A Novel Androgen Receptor Antagonist, in Patients With Metastatic Castration-Resistant Prostate Cancer.
Liu Y, He Y, Qi X, et al. · Clin Pharmacol Drug Dev 2024
- Clinical Application and Synthesis Methods of Deuterated Drugs.
Xu XL, Zhang W, Rao GW · Curr Med Chem 2023
- HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells.
Wu X, Feng W, Yang M, et al. · Mol Biol Rep 2022
- Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
Ma H, Xu W, Ni J, et al. · Prostate 2022
- Phase I clinical trial of HC-1119: A deuterated form of enzalutamide.
Li X, Cheng K, Li X, et al. · Int J Cancer 2021
Also in development for MCRPC
- REGN5678NezastomigPhase 23 trials
Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
- TYK-00540Phase 22 trials
TYK Medicines, Inc · mCRPC, HR-positive, HER2-negative Advanced Breast Cancer
- ZEN003694ZEN-3694Phase 22 trials
Zenith Epigenetics · mCRPC, Metastatic Castration-Resistant Prostate Cancer
- Ga-68-NGULPhase 21 trial
Cellbion Co., Ltd. · Prostate Cancer, mCRPC
- Lu-177-DGULPhase 21 trial
Cellbion Co., Ltd. · Prostate Cancer, mCRPC
- REGN21353Phase 21 trial
Regeneron · Metastatic Castration-Resistant Prostate Cancer, mCRPC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.